Home > Insider Trading > Filing (0001399529-21-000029)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1399529	Dicerna Pharmaceuticals Inc	DRNA	Pharmaceutical Preparations (2834)	205993609

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1813985	M. Regina Paglia	C/O Dicerna Pharmaceuticals, Inc. 75 Hayden Avenue Lexington MA 02421	Chief Human Resources Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-02-02	4,431	$12.93	4,431	No	4	M	Direct
Common Stock	Disposition	2021-02-02	4,431	$24.00	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2021-02-02	4,431	$0.00	4,431	$12.93

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
141,138		2029-02-28	No	4	M	Direct

Footnotes

The Reporting Person sold an aggregate of 4,431 shares of Common Stock on February 2, 2021(the "Shares Sold") as reported in this Form 4. The Shares Sold represent 1.48% of 300,319 shares of Common Stock, which is the number of shares of Common Stock owned by the Reporting Person prior to the Shares Sold transaction reported in this Form 4, as well as shares issuable upon exercise or settlement of vested and unvested options and restricted stock units held by the Reporting Person as of the date of this report.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 16, 2020.
The option vests 25% on the first year anniversary of the vesting start date of February 19, 2019 and the remaining 75% vests in 36 substantially equal monthly installments thereafter, subject in each case to the Reporting Person's continued service with the Issuer through each applicable vesting date.